← Back to Company DatabaseVisit Website
BillionToOne
Molecular diagnostics for cancer liquid biopsy and prenatal testing.
PublicMenlo Park, CAFounded 2015
About
BillionToOne developed a molecular counting technique called QCT that increases cell-free DNA diagnostics resolution by over 1,000 fold. Its Northstar Select liquid biopsy test guides therapy for stage III and IV cancer patients, while Northstar Response tracks treatment response. The company IPO'd in November 2025 after growing from $0 to $125M ARR in four years.
Total Funding
$389MKey Product
Northstar Select liquid biopsy testGeography
North AmericaKey Investors
Premji InvestAdams Street PartnersHummingbird Ventures
Focus Areas
DiagnosticsEarly Detection / Screening
Technology
Liquid BiopsyGenomics / Sequencing
Cancer Types
Pan-cancer
Last updated: Feb 4, 2026